What are the indications for percutaneous coronary intervention (PCI) and what are the different types of stents with detailed information about each?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 7, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Indications for Percutaneous Coronary Intervention and Stent Types

Drug-eluting stents (DES) should be your default choice for PCI to reduce restenosis risk, but only if the patient can tolerate and comply with 12 months of dual antiplatelet therapy (DAPT); otherwise, use bare-metal stents (BMS) or balloon angioplasty. 1

Indications for PCI

The primary indication for PCI is angina relief that translates into improved physical function and quality of life 2. PCI is performed across several clinical scenarios:

Acute Coronary Syndromes

  • STEMI (ST-elevation myocardial infarction): Primary PCI is the standard treatment
  • NSTEMI/Unstable Angina: PCI with appropriate stent selection based on bleeding risk and DAPT tolerance

Stable Coronary Disease

  • Symptomatic angina despite optimal medical therapy
  • Objective evidence of myocardial ischemia (though angiographically significant stenosis may justify PCI even without formal ischemia testing in severe lesions) 3

Special Circumstances

  • Chronic total occlusions (CTOs) for angina relief 2
  • Cardiogenic shock post-MI
  • Before noncardiac surgery (timing considerations critical) 4

Critical caveat: PCI should NOT be performed if the patient cannot tolerate or comply with DAPT - this is a Class III (Harm) recommendation 1.

Types of Stents: Detailed Breakdown

Bare-Metal Stents (BMS)

Composition: Stainless steel or cobalt chromium alloys 1

DAPT Duration: Minimum 30 days (risk of stent thrombosis greatest in first 30 days) 1

Use BMS when:

  • High bleeding risk exists
  • Patient cannot comply with 12 months of DAPT
  • Anticipated invasive or surgical procedures within 12 months that may require interrupting DAPT 1

Limitations: Higher restenosis rates compared to DES, requiring more repeat revascularizations 5

Drug-Eluting Stents (DES)

Four FDA-approved types in the United States 1:

1. Sirolimus-Eluting Stents

  • Demonstrated reduced need for repeat revascularization vs BMS
  • No increase in death or MI at 4-year follow-up
  • Requires 12 months DAPT 1

2. Paclitaxel-Eluting Stents

  • Reduced repeat revascularization vs BMS
  • No increase in death or MI at 4-year follow-up
  • Requires 12 months DAPT 1

3. Zotarolimus-Eluting Stents

  • Similar outcomes to sirolimus and paclitaxel stents
  • Reduced repeat revascularization vs BMS
  • Requires 12 months DAPT 1

4. Everolimus-Eluting Stents

  • Lower need for repeat revascularization than paclitaxel-eluting stents
  • By inference, lower risk than BMS
  • No increase in death or MI at 2-year follow-up
  • Requires 12 months DAPT 1

Key DES Characteristics

Common features across all DES 1:

  • Vary by scaffold material, design, drug content, and polymer for drug elution
  • Associated with delayed healing based on pathologic studies
  • Longer thrombosis risk period compared to BMS
  • More expensive than BMS (though cost-effective due to fewer repeat procedures)
  • Some practitioners extend DAPT beyond 12 months based on observational data, though RCTs haven't confirmed benefit

FDA approval trials: Originally recommended 3-6 months DAPT, but current consensus is 12 months to avoid late thrombosis 1

Specialized Stent Types

Covered Stents

  • Utilized for over 2 decades in PCI 6
  • Essential for managing complications
  • Design has evolved: improved deliverability, less bulky
  • Used for various coronary indications with mixed results 6

DAPT Algorithm by Clinical Scenario

For Elective PCI 1, 7:

  • BMS: Aspirin + clopidogrel for minimum 4 weeks, then aspirin indefinitely
  • DES: Aspirin + clopidogrel for 12 months, then aspirin indefinitely

For ACS (NSTEMI or STEMI) 7:

  • Both BMS and DES: Dual antiplatelet therapy for minimum 12 months regardless of stent type

Critical Decision Point: Pre-Implantation Discussion

Before implanting DES, you must discuss with the patient 1:

  1. The need for DAPT
  2. Duration of DAPT (12 months minimum)
  3. Patient's ability to comply with DAPT
  4. Patient's ability to tolerate DAPT (bleeding risk assessment)

Perioperative Management Pitfall

If noncardiac surgery becomes necessary after PCI, most patients can undergo surgery on DAPT when risk-benefit favors continued therapy. If P2Y12 inhibitor must be held, continue aspirin if bleeding risk permits. No validated "bridging" strategy exists (e.g., GP IIb/IIIa inhibitors, antithrombin therapy) 1. Resume P2Y12 inhibitor as soon as possible postoperatively.

Additional PCI Techniques

Beyond stent selection, other techniques include 5:

  • Thrombus aspiration
  • Direct stenting
  • Rotational atherectomy (Rotablation)
  • Cutting balloon angioplasty

Recent data shows DES and mechanical thrombectomy demonstrate superior angiographic success rates and improved clinical outcomes, particularly in complex lesion subsets 5.

Related Questions

If a patient is being considered for percutaneous coronary intervention (PCI), what loading doses of antiplatelet and anticoagulant medications should be administered?
What are the indications for percutaneous coronary intervention (PCI)?
How should I manage a 10-month-old infant with a rectal temperature of 100.6 °F and two episodes of vomiting?
What is the recommended evaluation and management for a 10-year-old male with pubic pain, intermittent dysuria for 2–3 months, decreased appetite, and urine specific gravity of 1.015?
What is the appropriate management for a 10‑month‑old infant with cough, wheezing, coarse breath sounds, and diarrhea?
In a 44-year-old woman (height 146 cm, weight 43 kg, BMI 20.2) with normal vital signs, normal renal and hepatic function, and no history of thromboembolic disease, malignancy, thrombophilia, or anticoagulant therapy, what is the risk of thromboembolic complications and surgical bleeding during a planned rectal polyp and hemorrhoidal nodule excision, and is pharmacologic thromboprophylaxis required?
Which hormones and neurotransmitters are associated with depression and anxiety?
Should I increase sertraline to 75 mg or increase the scheduled quetiapine (Seroquel) dose in a 76‑year‑old woman who remains aggressive on sertraline 50 mg daily and just received a 25 mg PRN dose of quetiapine?
What is the role of vitamin K in managing intracranial hemorrhage in a patient with an INR of 1.7?
What is the role of vitamin K in a patient with intracranial hemorrhage and an elevated international normalized ratio (INR) of 1.7 who is not on warfarin?
How do I quantify hypoxic burden in obstructive sleep apnea and what cardiovascular and mortality risks are associated with a high hypoxic burden?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.